December 09, 2016
The U.S. Federal Trade Commission asked a D.C. federal court Friday not to allow Boehringer Ingelheim Pharmaceuticals to delay producing documents related to a pay-for-delay suit over stroke prevention drug Aggrenox while the company appeals a decision on whether the documents are protected.
September 28, 2016
A D.C. federal judge found Tuesday that Boehringer Ingelheim Pharmaceuticals is protected by attorney-client privilege from disclosing the majority of subpoenaed financial documents in the Federal Trade Commission's pay-for-delay suit over stroke prevention drug Aggrenox.
September 27, 2012
A Washington federal judge ruled Thursday that many of the documents the Federal Trade Commission had sought from Boehringer Ingelheim Pharmaceuticals Inc. about its patent settlements with Barr Pharmaceuticals Inc. were privileged but ordered the drugmaker to quickly turn over the rest.
December 09, 2011
The Federal Trade Commission, on the hunt for documents relating to a patent settlement it is investigating between Boehringer Ingelheim Pharmaceuticals Inc. and Barr Pharmaceuticals Inc. that may have unlawfully delayed generic drugs, told a judge Friday that the documents contained factual material, not just attorneys' mental impressions.
October 27, 2009
The Federal Trade Commission, investigating a patent settlement between Boehringer Ingelheim Pharmaceuticals Inc. and Barr Pharmaceuticals Inc. that may have unlawfully delayed generic drug entry, has asked for a court order requiring Boehringer to comply with the terms of a subpoena.